Bisphosphonates and primary hyperparathyroidism.

Gideon A Rodan

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2003;17 Suppl 2():N150-3

PMID: 12412793

View on PubMed

Abstract

Bisphosphonates (BP) are pyrophosphate analogs that include very potent inhibitors of bone resorption. BPs act directly on the osteoclast, suppressing isoprenylation by inhibiting farnesyl diphosphate synthase in the cholesterol pathway, which causes osteoclast inactivation. BPs should therefore reduce the bone loss produced by any cause, including hyperparathyroidism and hypercalcemia of malignancy (MIH), caused by parathyroid hormone (PTH) and PTH-related protein (PTHrP), respectively. BPs at higher doses than used in osteoporosis are indeed the treatment of choice for malignancy-induced hypercalcemia. Limited, but convincing, data show that BPs at doses effective in osteoporosis also reverse bone loss associated with mild primary hyperparathyroidism (PHPT).

Address: Department of Bone Biology and Osteoporosis Research, Merck & Co., West Point, Pennsylvania 19846, USA.

Link outs

Free resources

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-PTHrP-1

MeSH Terms: Alkyl and Aryl Transferases, Bone Resorption, Carcinoma, Diphosphonates, Geranyltranstransferase, Humans, Hypercalcemia, Hyperparathyroidism, Osteoclasts, Osteoporosis, Parathyroid Hormone, Parathyroid Hormone-Related Protein, Parathyroid Neoplasms, Peptide Hormones